Rasna Therapeutics, Inc.

Common Stock SEC Reporting - Delinquent
Contact Info
  • 420 Lexington Avenue
  • Suite 2525
  • New York, NY 10170

Business Description

Update Company Profile
Financial Reporting/Disclosure
Reporting Status U.S. Reporting: SEC Reporting
Audited Financials Audited
Latest Report Sep 30, 2016 10-Q
CIK 0001582249
Fiscal Year End 6/30
OTC Marketplace OTCQB
Profile Data
SIC - Industry Classification 2834 - Pharmaceutical preparations
Incorporated In: NV, USA
Year of Inc. 2012
Employees 8 a/o Oct 31, 2016
Company Officers/Contacts
James Tripp CEO
Tiziano Lazzaretti CFO
Company Directors
Alessandro Padova Chairman, Independent Director
John P. Brancaccio Independent Director
Riccardo Dalla-Favera Independent Director
John Alex Martin Independent Director
Jim Mervis Independent Director
Kunwar Shailubhai Independent Director
James Tripp
Service Providers
Accounting/Auditing Firm
945 E Park Drive
Suite 103
Harrisburg, PA, 17111
United States
Securities Counsel
Sheppard, Mullin, Richter & Hampton LLP
12275 El Camino Real
Suite 200
San Diego, CA, 92130
United States
Investor Relations Firm

Not Available
Company History
  • Formerly=Active With Me Inc. until 9-2016
RASP Security Details
Share Structure
Market Value1 $135,827,576 a/o Feb 22, 2017
Authorized Shares 200,000,000 a/o Sep 29, 2016
Outstanding Shares 64,679,798 a/o Nov 09, 2016
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float 5,866,254 a/o Sep 29, 2016
Par Value 0.001
Transfer Agent(s) Verified by Transfer Agent
Philadelphia Stock Transfer, Inc.
Shareholders of Record 67 a/o Sep 29, 2016
Short Selling Data
Short Interest 0 (-100%)
Dec 15, 2016
Significant Failures to Deliver No

1Market Value calculated only for respective security